NCT04704661 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
7 trialsNCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT06929260 2026-01-22
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
AstraZeneca
Phase 1 Terminated
NCT03328273 2026-01-12
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 1 Active not recruiting
NCT04550104 2025-12-19
CONCORDE
University of Leeds
Phase 1 Recruiting
NCT03770429 2025-09-29
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT02223923 2025-08-01
Patriot
Royal Marsden NHS Foundation Trust
Phase 1 Unknown